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FoldingHelix–helix interactions play a central role in the folding and assembly of integral α-helical membrane
proteins and are fundamentally dictated by the amino acid sequence of the TM domain. It is not surprising
then that missense mutations that target these residues are often linked to disease. In this review, we focus on
the molecular mechanisms through which missense mutations lead to aberrant folding and/or assembly of
these proteins, and then discuss pharmacological approaches that may potentially mitigate or reverse the
negative effects of these mutations. Improving our understanding of how missense mutations affect the
interactions between TM α-helices will increase our capability to develop effective therapeutic approaches to
counter the misassembly of these proteins and, ultimately, disease. This article is part of a Special Issue
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Integral α-helical membrane proteins play a fundamental role in
cell viability, from acting as one of the initial members in a series of
cell-signaling events, to transporting and regulating cellular levels of
both small and large molecules to provide the required conditions for
survival. These largely hydrophobic polypeptide chains fold into
various membrane-bound organizations, including single- and multi-
spanning transmembrane (TM)2 domains coupled with both extra
and intra-cellular soluble domains ranging widely in number and size.
The assembly of eukaryotic membrane proteins requires a level of
complexity above that of their cytoplasmic counterparts, because
membrane proteins are extremely hydrophobic andmust undergo the
additional step of being threaded into the hydrophobic lipid bilayer.
Membrane protein folding has been simpliﬁed into a two-stage
model, with insertion and α-helical formation of the nascent polypep-
tide in themembrane comprising theﬁrst stage, followedbyhelix–helix
association into tertiary and/or quaternary structures [1]. To facilitate
this process and ensure that the membrane-integrated protein is
properly assembled, the cell has evolved systems of coordination and
quality control collectively known as the proteostasis network (forrecent reviews, see [2,3]). However, even with these systems in place,
the assembly efﬁciency of many of these proteins is less than 50% at
body temperature [4] and may explain why a change in amino acid
sequence at a single site is enough to cause misassembly, leading to
disruptionof theproteostasis networkand, ultimately, humandisease. It
would seem then that many membrane proteins exist literally on the
edge of aggregation [5].
The TM α-helices of membrane proteins are a frequent target for
disease-causingmissensemutations [6–8]. This is not surprising given
their signiﬁcant role in membrane protein assembly [9]. In this
review, we ﬁrst demonstrate the importance of both TM α-helix
sequence and helicity for their interactions with lipids and/or other
helices to form speciﬁc higher-ordered structures — situations that
can easily be altered via a single missense mutation resulting in a
disease-causing misassembly of the protein. In subsequent sections,
we focus on the molecular mechanisms through which these
mutations cause membrane protein misassembly by disrupting or
strengthening the helix–helix interactions within the TM domain, and
recent approaches as to how such misfolding might be reversed.
2. Proteins in membranes —mutual accommodation of structures
The notion of a distinct hydrophobic/hydrophilic division by the
plasma membrane does not convey the actual complexity of its
structure. The membrane consists mainly of glycerophospholipids
with a ~30 Å hydrophobic core of lipid acyl-chains of varying lengths
and a ~15 Å interfacial region on either side containing polar head
groups and water molecules that gradates into the bulk water
(Fig. 1A) [10]. In higher animals, lipid side chains consist predomi-
nantly of 16 or 18 carbons with between 0 and 3 cis-double bonds,
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Fig. 1. Lipid structure and membrane protein helix–helix interactions. (A) A space-ﬁlling representation of the lipid bilayer. (B) Helix–helix interactions in the TM domains of GpA,
phospholamban, and T-cell receptor. The TMα-helices of each protein are rendered as ribbons and the residues mediating the helix–helix interactions are highlighted as space-ﬁlling
models. See Section 2.2 in the text for the identity of the residues in the interaction interfaces.
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the presence of cholesterol modulates the ﬂuidity of the membrane.
Interestingly, lipid composition varies in a tissue-speciﬁc manner and
likely plays a signiﬁcant role in protein folding which makes the
understanding of membrane protein folding more challenging.
2.1. Sequence dictates membrane insertion
The principal requirement for a membrane protein TM domain is a
stretch of ~18–25 amino acids that is energetically satisﬁed in the
hydrophobic lipid bilayer. While soluble proteins generally consist of
a melange of secondary structures including α-helices, β-sheets, and
random-coiled regions, membrane proteins are limited by the
hydrophobic environment of the lipid bilayer to α-helices or β-
barrels since these structures can self-satisfy the H-bonding potential
of the polar peptide backbone [11].
A TMdomain does not explicitly contain only hydrophobic residues:
approximately 20% of residues in the membrane are polar [12]. In this
case, the energetic cost of introducing a polar or charged residue into a
hydrophobic environment is likely offset by interactions with another
polar residue or the peptide backbone (as is the case in some
oligomerization motifs). As well, the formation of water- or ion-lined
pores, snorkeling of amino acid side chains, and deformation of the
membrane or helix to interact with the aqueous phase or lipid head
groups, could alleviate the cost of placing polar substituents in the
hydrophobic environment [13,14]. Additionally, the remaining residues
on the TM segment are often correspondingly elevated in hydropho-
bicity in order to yield an overall threshold hydrophobicity that is
permissive for membrane insertion [15]. Although several in vitro
hydrophobicity scales for the 20 amino acids have been presented [16],
seminalwork byvonHeijnehas led to the identiﬁcation of thepositional
insertion requirements using an in vivo translocon assay [17,18]. The
residues that are decidedly hydrophobic andwill promote insertion into
themembranewhen placed in themiddle of the helix are (frommost to
least favorable): Ile, Leu, Phe, Val, Met, and Cys. As a general trend, polarresidues are typically located near the ends of the helix and are likely to
interact with the polar head groups and water molecules in the
interfacial region of the membrane.
2.2. Helix–helix interactions in the membrane
The insertion of a TM α-helix in the membrane is the ﬁrst
determinant of a membrane protein, yet the fate of the protein is
dependent on the helix stability in this environment: the helix will
either remain solvated by lipid as a single-spanning monomeric
membrane protein, or the helix will only be partially solvated, driving
two or more helices together. Althoughmembrane protein helices are
solvated by lipid, acyl chains are not the ideal solvent for hydrophobic
side chains that protrude irregularly into the cross section of the lipid
bilayer. This relative instability promotes helix–helix interactions that
will form at faces that are the least lipid-accessible [19]. These
interactions occur largely via van der Waals or polar/electrostatic
interactions, and involve speciﬁc sequence motifs that either fold the
protein into its tertiary structure or allow for quaternary oligomer-
ization. Outlined in Table 1 are the known eukaryotic interaction
motifs, among which the more common are described below.
2.2.1. GG4, GASright, or right-handed motifs
It was noted that in nature, there is an abundance of Gly residues in
TMα-helices that are found in GxxxG sequencemotifs [20]. The right-
handed packing of helices is mediated by Gly's that are separated four
residues apart (hence GG4), placing them on the same helix face; in a
side view of such a helix, the Gly residues are located one above the
other due to the 3.6 residues per turn geometry of an α-helix [21]
(Fig. 1B).
The prototypical dimer, glycophorin A (GpA), is a single-spanning
human erythrocyte glycoprotein associated with blood group determi-
nation that employs a LIxxGVxxGVxxT dimerization sequence [22–25].
The Gly residues appear as ‘holes’ in the helix surface and dimerization
occurs due to ‘knobs-into-holes’ packing, with the adjacent Val ‘knob’
Table 1
Experimentally-determined eukaryotic transmembrane oligomerization motifs.
Proteina Transmembrane sequenceb Oligomer state Ref
GG4 (GASRight/Right-handed)
GpA 72EITLIIFGVMAGVIGTILLISYGIRRL98 Dimer [22,24,25]
MPZ 125YGVVLGAVIGGVLGVVLLLLLLGYVV150 Dimer [73]
ErbB-2 651LTSIVSAVVGILLVVVLGVVFGILI675 Dimer [33,74,75]
BNIP3 164VFLPSLLLSHLLAIGLGIYIGR185 Dimer [76]
NRP1 857ILITIIAMSALGVLLGAVCGVVLY880 Dimer [77]
EphA1 548IVAVIFGLLLGAALLLGILVF 568 Dimer [78]
RPTP
DEP1
976VICGAVFGCIFGALVIVTVGGFIFW1000 Dimer [79]
APPc 700GAIIGLMVGGVVIATVIVITLVML723 Dimer [80]
APPc 700GAIIGLMVGGVVIATVIVITLVML723 Dimer [81]
Kitl TMD 215WTAMAFPALISLVIGFAFGAFYW237 Dimer [82]
AdipoR1
TM5
268AGVFLGLGLSGVVPTMHFTIA288 Dimer [83]
Na,K-β 36LLFYVIFYGCLAGIFIGTIQVMLLTI61 Dimer [84]
ABCG2
TM1
394ASIAQIIVTVVLGLVIGAIYFGL416 Dimer [85]
Syn TM2 145VLAAVIAGGVIGFLFAIFLILLLVY169 Dimer [86]
Syn TM3 385VLVAVIVGGVVGALFAAFLVTLLIY409 Dimer [86]
Syn TM4 146VLAALIVGGIVGILFAVGLILLLMY170 Dimer [86]
hCTR1d 136TVLHIIQVVISYFLMLIFM154 Trimer [87]
Heptad (GASLeft/Left-handed)
PLB 31LFINFCLILICLLLICIIVMLL52 Pentamer [30,31,88]
PDGFβRe 531KVVVISAILALVVLTVISLIILIMLW556 Dimer or trimer [89]
EphA2 535LAVIGGVAVGVVLLLVLAGVGFFI558 Dimer [90]
SR-BI 9WVALGLGALGLIFAALGVVMILMVPSLI36 Dimer [91]
DDR1 418ILIGCLVAIILLLLLIIALMLW439 Dimer [92]
ANTXR1 318ILAIALLILFLLLALALLWW337 ≥Dimer [93]
Polar
TNF5 26YLLTVFLITQMIGSLFAVYL46 ≥Dimer [94]
TCR
ζ-chain
28DSKLCYLLDGILFIYGVILTALFLRVKFSR57 Dimer [32]
Ii 30GALYTGFSILVTLLLAGQATTAYFLY55 Trimer [95]
RET 635RTVIAAAVLFSFIVSVLLSAFCI657 ≥Dimer [96]
DAP12 7GVLAGIVMGDLVLTVLIALAVYFL30 Dimer [97]
FUT3 17LAALLFQLLVAVCFFSYL34 ≥Dimer [94]
Hetero-oligomers
αIIb 968WVLVGVLGGLLLLTILVLAMK988 Dimer, reciprocal
large-small motif
[98]
β3 693ILVVLLSVMGAILLIGLAALLIWK716 [98]
ErbB-1 645SIATGMVGALLLLLVVALGIGLFM677 Dimer [99]
ErbB-2 651LTSIVSAVVGILLVVVLGVVFGILI675 [33,74,75]
DAP12 7GVLAGIVMGDLVLTVLIALAVYFL30 Trimer [97]
NKG2C 61ELFPILVITKLVTAVLVISIIGLV38 (DAP12 dimer+
NKG2C)
a GpA, human erythrocyte protein glycophorin A; MPZ, myelin protein zero; ErbB-2,
epidermal growth factor receptor tyrosine kinase 2; BNIP3, Bcl-2/19 kDa interacting
protein 3; NRP1, neuropilin-1; EphA1, erythropoietin-producing hepatocellular
receptor A1; RPTP DEP1, human receptor-like protein tyrosine phosphatase; APP,
Alzheimer precursor protein; Kitl, mouse stemcell factor Kit-ligand; AdipoR1 TM5,
human adiponectin receptor; Na,K-β, Na,K-ATPase β-subunit; ABCG2 TM1, human ABC
multidrug transporter G subfamily; Syn TM2, syndecan; Syn TM3, syndecan; Syn TM4,
syndecan; hCTR1, human copper transporter 1; PLB, cardiac phospholamban; PDGFβR,
platelet-derived growth factor β-receptor; EphA2, erythropoietinproducing hepatocellular
receptor A2; SR-BI, HDL Scavenger receptor class B type I N-terminal TMD; DDR1, human
discoidindomain receptor tyrosinekinase1;ANTXR1, anthrax toxin receptor1;TNF5, tumor
necrosis factor 5/CD40-ligand; TCR ζ-chain, T-cell surface glycoprotein CD3; Ii, class II MHC
receptor Ii protein; RET, RET receptor tyrosine kinase; DAP12, TYROprotein tyrosine kinase-
binding protein; FUT3, fucosyltransferase 3; αIIb, human platelet membrane glycoprotein
αIIb; β3, human platelet membrane glycoprotein β3; ErbB-1, epidermal growth factor
receptor tyrosine kinase 1; NKG2C, natural killer cell-activating receptor.
b The numbering indicates the start and end residue number in the natural TM
domain. Residues determined to stabilize TM association are underlined.
c Two dimer sites have been proposed for APP.
d hCTR1 utilizes a unique MxxxM right-handed motif.
e Bolded residues are used in addition to the underlined residues by PDGFβR to form
a trimer.
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Recentwork suggests that GG4 interactionsmay bemore complex than
previously thought, with the identities of the ‘knob’ residues playing animportant role in the oligomerization strength of this interaction [26]. In
the latter study, it was determined that the adjacent Val residues can be
replacedwith Ile, but not Leu or Ala, in order tomaintain dimerization, a
result which suggests a requirement for β-branched residues at this
location. Other possible interactions in the motif are weak H-bonding
between Cα-H groups on one helix and the carbonyls of the opposite
helix [27,28]. Nevertheless, the speciﬁc role(s) of Leu and Ile residues in
this GpA local sequence are not fully understood, yet likely form further
van der Waals interactions as mutation of these residues affect
dimerization. The remaining Thr forms polar interactions with the
backbone of the opposite monomer.
These sequences are also referred to asGASright since theyhave right-
handed crossing angles and other small residues such as Ala and Ser can
replace the Gly in the GG4 motif [21]. Although only a handful of GG4
motifs have been structurally characterized, these oligomerization
sequences likely play a major role in both tertiary and quaternary
helix–helix interactions inmembrane proteins due to themanypossible
combinations of Gly, Ala, and Ser that occur four residues apart in TM
sequences.
2.2.2. Heptad, GASleft, or left-handed motifs
As with the GG4 motif, Gly, Ser, and Ala residues can accommodate
the close approach of helices in a typical heptad repeat which leads to
left-handed crossing angles [21,29]. Examples of the GASleft motif are not
as commonas theGASrightmotif. However, due to the increased tendency
of small residues to situate in heptad motifs, it is likely that these motifs
are commonly found in nature, especially in tertiary contacts.
The heptad repeat can also contain large residues, as in the case of
the Leu-Ile zipper, which drives the oligomerization of the phospho-
lamban pentamer [30,31] (Fig. 1B). Phospholamban is found in
cardiac sarcoplasmic reticulum and is associated with the regulation
of calcium pump activity. This membrane protein utilizes an
IxxxLxxIxxxLxxIxxxL heptad repeat (typiﬁed with letters abcdefg),
with the Leu residues at the a positions and the Ile at the d positions,
resulting in the large hydrophobic residues lining a single face of a
helix while mediating helix–helix contacts via van der Waals packing
interactions.
2.2.3. Polar motifs
Polar residues in the membrane often lead to hydrogen bonding
between the side chains of two or more helices. These categories of
oligomerization sequences are highly variable and can arise from an
interaction between a single polar residue on each helix or from
interactions between multiple residues on each helix face. An
example is the T-cell receptor ζ-chain, which serves as a portion of
the T-cell receptor complex that is responsible for recognizing
antigens bound to the major histocompatibility complex. The T-cell
receptor ζ-chain utilizes polar residues in a DxxLxxYxxxLT motif to
form an H-bonded dimer in the membrane that includes an Asp-Asp
inter-monomer interaction and Tyr-Thr, Thr-Tyr interactions [32]
(Fig. 1B). Other interactions that have been determined to mediate
helix–helix interactions in the membrane via polar/electrostatic
mechanisms include cation–π and π–π between aromatic and/or
basic amino acids [33–36].
3. Missense mutations and disease — molecular mechanisms
In this section of the review, we focus on the molecular
mechanisms through which missense mutations in the TM domain
of membrane proteins lead to misassembly. We deﬁne misassembly
here as broadly encompassing both defects in tertiary (misfolding)
and quaternary (aberrant oligomerization) structure formation.
Misassembled species may ultimately cause disease by affecting the
normal trafﬁcking of the protein, resulting in, but not limited to,
decreased amounts of functional protein at the destination mem-
branes; entrapment of toxic gain-of-function protein in the ER; and/or
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invoke the unfolded protein response and apoptosis [37]. Alterna-
tively, misassembled membrane proteins may arrive at their destined
membranes but their abnormal functions lead to disease [38].
3.1. Disrupting helix–helix interactions
Membrane protein assembly is highly dependent on TM α-helices
interacting in a sequence-speciﬁc manner (as exempliﬁed by the
numerous interaction motifs listed in Table 1). These interactions can
loosely be categorized into those that allow for optimal van der Waals
packing and/or polar/electrostatic interactions. It follows that non-
conservative missense mutations to the residues in these motifs (i.e.,
polar to non-polar, large to small) would impose a folding burden on a
TM domain, and potentially cause membrane protein misassembly
(Fig. 2). For example, conversion of glycine's side chain volume from
small to that of a larger residue would interrupt the tight “knobs into
holes” packing found at GG4 interfaces. Similarly, mutating away the
H-bonding capacity of a residue at an interaction interface would be
disruptive if the α-helices are held together by H-bonds.
The strength of association mediated by a helix–helix interaction
motif is heavily inﬂuenced by variables such as the context of
surrounding residues and position of themotif relative to the center of
the bilayer [39–41], which suggests that disruptive missense
mutations would have wide-ranging effects on misassembly depend-
ing on the location of the motif. This might be a factor in why different
disease-causing mutations in the TM domain of membrane proteins
can show variation in the severity of disease-phenotype [42].
3.1.1. Examples of disease-causing mutations that cause misassembly via
disrupted helix–helix interactions
There are several known membrane protein-linked diseases that
are a result of non-conservative mutations that disrupt folding and/or
oligomerization. For example, the mutation V509A in the thyrotro-
phin receptor alters the tertiary interactions of the membrane protein
by disrupting the tight van der Waals packing between TM3 and TM5.
This disruption imbues the helices with more conformational
ﬂexibility and increases the activity of the receptor, which in turn
leads to congenital hyperthyroidism [43].
In the case of quaternary structure disruption, the G163R and
G167R mutations in the TM α-helix of myelin protein zero — a cell
adhesion membrane protein found in the cellular membrane of
Schwann cells — are associated with Charcot–Marie–Tooth disease
and Dejerine–Sottas syndrome [44]. These mutations target the small
residues of the glycine-zipper motif found in the helix of this protein,Fig. 2. Effects of missense mutations on membrane protein structure. The hairpins
represent the TM domain of a simple membrane protein where the yellow and blue
cylinders are individual TM α-helices linked together via a loop. Missense mutations
can affect helix–helix interactions within a protein monomer or between oligomers by
changing the strength of the interactions. Red Xs and bars represent disrupting and
strengthening mutations, respectively.weakening the tight packing interactions and likely disrupting proper
tetramer formation [45]. Similarly, in connexin26, the mutation
T135A abolishes the H-bonding capacity of TM3 and destabilizes the
hexameric oligomer, leading to hereditary deafness [46].
Disruption of helix–helix interactions is not limited to non-
conservative missense mutations. Mutations that are traditionally
considered conservativemay also have an effect if the speciﬁc property
modulating the interaction is targeted. For example, Glu325 in TM10of
the E. coli lactose permease normally interacts with Arg302 in an
adjacent helix. However, mutating this residue to a similarly charged
side chain, Asp, reduces transport activity. This phenomenon is
attributed to the shortened side chain in themutant, which apparently
weakens the H-bonding interaction with the partner residue [47]. As
seen in this example, non-conservative missense mutations could
foreseeably be disruptive in disease-associated membrane proteins.
3.2. Strengthening helix–helix interactions
Missense mutations can also strengthen or create helix–helix
interactions that can lead to membrane protein misassembly (Fig. 2).
In the case of an existing helix–helix interaction site, mutation of
residues at or near the interaction interface may further stabilize or
enhance the interaction. For example, in the classic dimerizationmotif
of GpA, mutating the Val residues immediately adjacent to Gly79 and
Gly83 to other large hydrophobic residues enhances the extent of
dimerization relative to the wild-type protein [26]. A similar effect is
seen if a Phe is added to the −3 position relative to Gly79 [48].
Alternatively, a missense mutation could ostensibly generate a novel
helix–helix interaction site in the TM α-helix and drive non-native
helix associations; thus, the introduction of polar residues to a
hydrophobic peptide can drive helix–helix interactions in the
membrane [49]. The strengthening/creation of helix–helix interac-
tions could be deleterious for membrane protein assembly, because
they could promote non-native conformations within the TM domain
of a protein chain and/or aberrant oligomerization between protein
chains.
3.2.1. Mutations that cause misassembly via strengthened helix–helix
interactions
Cystic ﬁbrosis has been attributed to ER trafﬁcking defects caused
by misassembly of the cystic ﬁbrosis transmembrane conductance
regulator (CFTR). Our lab previously showed that themutation V232D
in a hairpin construct containing the TM3 and 4 α-helices of CFTR
could potentially lock the two helices into a compact conformation
through the formation of a non-native interhelical H-bond [50]. The
tightly interacting helices may restrict the dynamics/ﬂexibility
required for channel function and/or reorient the helices, changing
the overall protein fold. A similar scenario is seen for themelanocortin
4 receptor (MC4R) — a GPCR that plays a role in energy homeostasis.
Several missense mutations in the TM domain increase the helix
packing and/or H-bonding interactions between the helices, effec-
tively locking the receptor in an inactive conformation, leading to
dominantly inherited human obesity [51].
Strengthening of helix–helix interactions can also affectmembrane
protein oligomerization. An I655Vmutation in the TMα-helix of ErbB2
(human epidermal growth factor receptor) has been shown to
increase the risk of breast cancer. This is likely due to the stabilizing
effect of the mutated residue on the nearby SxxxG interaction motif,
which increases the population of the active conformation of the
receptor dimer [38]. Additionally, in the rat ErbB2 homologue neu, a
mutation of V664E also leads to permanent dimerization and
activation of the receptor, resulting in the formation of tumors [52].
This phenomenon has been mainly attributed to H-bonding between
Glu residues of themonomers [53]. However, otherworkers presented
evidence that the Glu residues do not interact directly, and the
stabilization of the active conformational form of the dimer is a result
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helix–helix interaction motif over another [54]. In either case, the
outcome of themutation is an increase in helix–helix interactions that
leads to aberrant oligomerization.
3.3. Misassemblydue tomissensemutations changinghelix–lipid interactions
The helix–helix interactions that assemble membrane proteins can
be greatly affected by the lipid bilayer inwhich the TMα-helices reside.
Depending on the difference in property between helix andmembrane,
the effect can strengthen or disrupt helix–helix interactions. One such
property is the hydrophobic length or thickness of a TMα-helix relative
to that of the lipid bilayer. If the lengths do not match, the helix might
change its conformation in order to accommodate this hydrophobic
mismatch [55]. In the situation where the helix is interacting with
another helix, this change in conformation could either enhance or
disrupt the interaction. For example, when the dimerization of GpA is
examined in lipid bilayers of varying thicknesses, the extent of
dimerization decreases when there is hydrophobic mismatch [56].
This effect has been attributed to a change in the tilt angle of the TM
helices, resulting in a less efﬁciently packed helix interaction interface.
Other lipid–protein interaction properties that might affect the
assembly of TM α-helices could include lipid solvation of the helix
[19], and occurrence of interfacial-lipid anchoring residues in the helix
termini [57,58]. Missense mutations that alter these properties could
have foreseeable consequences on helix–helix interactions, resulting in
membrane protein misassembly.
3.4. Missense mutations and misassembly in multi-spanning membrane
proteins
Helix–helix interactions are important in mediating the assembly of
both single-spanning and multi-spanning membrane proteins. The
main difference is that when a membrane protein is comprised of a
single TM α-helix, any helix–helix contacts would mediate only
quaternary structure, whereas for membrane proteins containing
multiple helices, these contacts can mediate both tertiary and
quaternary structure [59]. This situation indicates that the effect of
missense mutations on membrane protein misassembly would be
considerably more complex in multi-spanning vs. single-spanning
membrane proteins. For example, a mutation in the TM domain of a
polytopic species could hypothetically affect its oligomerization state by
(1) directly affecting the helix–helix interaction sites mediating the
oligomer; or (2) affecting thehelix–helix interactionsmediating the fold
of the monomer that would then indirectly affect the interactions
mediating the oligomer. It is possible that a missense mutation that
disrupts the monomer fold of a multi-spanning membrane protein
might allow interaction sites that are normally masked by the properly
folded protein to become surface-accessible, leading to aberrant
assembly of the protein oligomer [5]. This type of mechanism may
underlie disease-causing point mutations in the myelin proteolipid
protein that initiate premature oligomerization and results in Pelizaeus–
Merzbacher disease [8,60]. In an analogousmanner, the L16P Trembler-J
mutation in the TM1 (and, perhaps, the G150D Trembler mutation in
TM4) of peripheral myelin protein 22 likely results in disease by
disrupting the protein's tertiary fold, which exposes the TM1 α-helix
such that calnexin aberrantly binds to it, leading to the retention and
toxic accumulation of the misassembled protein in the ER [61].
4. Can disease-phenotypic misassembly be reversed?
Membrane proteinmisassembly causes disease either by the protein's
inability to trafﬁc to the proper membrane or by its improper function
once successfully at themembrane. In either case, we can conceivably use
pharmacological molecules to regain trafﬁcking to the membrane or to
alter the misfolded product to restore function. Furthermore, anexogenous molecule could be used to inhibit or modulate a properly
functioning protein that is giving an undesired effect in a given scenario.
A protein mutation that is conceivably functional, yet gives a
diseased phenotype, often occurs due to proteins being ﬂagged as
misfolded by the ER quality control system. This results in ER-trapped
proteins that cannot successfully trafﬁc to the cell surface for function. A
potential treatment for this condition came in the form of small, non-
peptide molecules (termed ‘pharmacoperones’), originally identiﬁed as
GPCR antagonists, that were able to selectively rescue cell surface
expression and function of mutant GPCRs [62,63]. The general
mechanism of action by these pharmacoperones is thought to consist
of the molecule penetrating the plasma and ER membranes to bind to
the partially folded receptor. This binding shifts the thermodynamic
equilibrium towards the correctly folded conformation and results in an
increased amount of protein that is then able to escape the stringent
quality control systemof the ER and reach the cell surface [64] (Fig. 3A).
To-date, the trafﬁcking of four misfolded GPCRs that cause disease has
been rescued by the use of these pharmacoperones: rhodopsin causing
retinitis pigmentosa (e.g., 9-cis-retinal) [65]; vasopressin type 2
receptor causing nephrogenic diabetes insipidus (e.g., satavaptan)
[66]; gonadotropin-releasing hormone receptor causing hypogonado-
tropic hypogonadism (e.g., indoles) [67]; and calcium-sensing receptor
causing familial hypocalciuric hypercalcemia (e.g., NPS R-568, N-(3-[2-
chlorophenyl]propyl)-(R)-α-methyl-3-methoxybenzylamine) [68].
Given the high number of membrane protein misfolding leading to
improper trafﬁcking, and ultimately disease, the numbers of pharma-
coperones could be greatly increased.
Misassembled proteins that successfully trafﬁc to themembrane can
also lead to disease by a loss or gain of function and/or oligomerization.
Small molecules that could interact with either the TM domains or the
loop regions of such proteins would be ideal in correcting this
misassembly. A further possibility would be the use of TM peptide
fragments that could interact with the helix of a naturally occurring
defective membrane protein. Endogenous TM segments oftenmodulate
function of membrane proteins, and peptides that mimic this control
could be employed in disease treatment (Fig. 3C). A study of the Na/K-
ATPase sodium pump determined that its enzymatic activity—which is
normally regulated by a γ-subunit — was modulated by synthetic
peptidesmimicking theγ-subunit [69]. Similarly, the calciumchannelγ6
subunit inhibits Cav3.1 low voltage-activated calcium current in human
embryonic kidney cells and cardiomyocytes using a critical GxxxAmotif
in TM1. Thus, with an eight-residue peptide where the native sequence
contains this GG4 motif, speciﬁc inhibition was obtained of the Cav3.1
calcium current, a ﬁnding that has implications for future use as in a
therapeutic context after myocardial infarctions [70].
Inhibiting homo-oligomerization by peptides may also be an area
of disease treatment (Fig. 3B). As proof of principle, this has been
accomplished using peptides that target the Class II G-protein coupled
secretin receptor, which functionally oligomerizes at TM4. It was
found that by synthesizing TM4 peptides of an identical sequence to
the native GPCR and treating cells expressing the GPCR with such
peptides, the function of the GPCRwas reduced [71]. Furthermore, the
single-spanning membrane protein ErbB2 is a tyrosine kinase
receptor for the epidermal growth factor (EGF) that via a mutation
can be constitutively activated as a dimer leading to cancer. Both
synthetic peptides and short vector-encoded fusion peptides with the
native TM sequence speciﬁcally inhibit the ErbB2 dimerization, thus
abolishing the signaling pathway [72]. Although the examples of
peptides targeting TM domains are few, it is a promising area of study
if the proper conditions for treatment by largely hydrophobic peptides
can be devised.
5. Concluding remarks
The amino acid sequences of membrane protein TMα-helices have
been shown to play a demonstrably signiﬁcant role in directing the
Fig. 3. Reversing membrane protein misfolding through a pharmacological approach. The cylinders represent the TMα-helices of membrane proteins. (A) Pharmacoperones (green)
correct misfolded membrane proteins and allow them to escape the ER quality control system. (B) Mutations that increase the strength of helix–helix interactions or create novel
interaction sites in the TM domain of a membrane protein may be corrected in a competitivemanner by a TM peptide containing the wild-type sequence of the helix partner. (C) The
helix–helix interactions of two membrane proteins that are disrupted by mutations may be rescued through the use of exogenous peptides that mimic the wild-type TM α-helix
sequence(s) of the mutated protein.
1120 D.P. Ng et al. / Biochimica et Biophysica Acta 1818 (2012) 1115–1122helix–helix interactions that lead to correct folding and assembly of
these proteins. As such, even a single missense mutation at a critical
site on a helix can be detrimental to the folding and/or function of the
protein. Our increasing knowledge of the mechanisms through which
a membrane protein assembles into its native structure is now
providing new insights as to how mutations can compromise this
process. Improvement of our understanding of these concepts will
allow us to increase our arsenal of approaches to counter membrane
protein misassembly — and ultimately human disease.
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